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Background: The importance of B7-H molecules for the T cell/tumor communication and its impact on renal cell
carcinoma (RCC) progression and prognosis has been recently described. Cytokine treatment of RCC has earlier
been shown to be beneficial in preclinical settings, but its clinical implementation has not proven to be as effective.
This might be partially explained by the yet incomplete picture of cellular alterations in tumor cells upon cytokine
treatment investigated in detail in this study.
Methods: RCC tumor cell lines were treated with different cytokines alone or in combination. The constitutive and/or
cytokine-induced expression of cytokine receptors signaling components and B7-H molecules in RCC cells were analysed
by qPCR and flow cytometry. A mcherry reporter gene construct containing B7-H1 promoter was cloned and its activity
was determined upon transfection in cytokine-stimulated cells. Cytokine pretreated tumor cells were co-cultured with
allogeneic CD8+ T cells from healthy donors and T cell proliferation as well as cytokine secretion was determined.
Results: A heterogeneous, but constitutive B7-H1,-H2,-H3 and H4 expression was found on human RCC cell lines. IL-4
and TNFα treatment led to strong synergistic induction of B7-H1 in RCC cells, whereas B7-H2 was only increased by
TNFα. In contrast, B7-H3 and B7-H4 expression were not altered by these cytokines. Treatment of RCC cells with TNFα
and IL-4 was accompanied by an activation of signaling molecules like NF-κB, IκB and STAT6. The cytokine-mediated
up-regulation of B7-H1 was due to transcriptional control as determined by an increased B7-H1 promoter activity in
the presence of IL-4 and TNFα. Despite HLA class I and LFA-1 were also increased, the cytokine-mediated up-regulation
of B7-H1 was more pronounced and caused an inhibition of allospecifc CD8+ T cell proliferation.
Conclusion: Thus, IL-4 and TNFα, which could be released by immune cells of the tumor microenvironment, are
able to control the B7-H1 expression in RCC thereby altering T cell responses. These data are of importance for
understanding the complex interplay of tumor cells with immune cells orchestrated by a number of different soluble
and membrane bound mediators and for the implementation of check point antibodies directed against B7-H1.
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Renal cell carcinoma (RCC) is the most common kidney
cancer type with an incidence of 5.8 in 100.000 people
in the Western world [1] causing death of 5327 patients/
year in Germany [2]. These results document the need
for ongoing research to identify novel therapeutic strat-
egies and to investigate mechanisms of tumor immune
escape. RCC is considered an immunogenic tumor as* Correspondence: barbara.seliger@uk-halle.de
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mune cells, a relatively high incidence of spontaneous re-
currences as well as by the efficacy of immunotherapies,
like DC-based vaccines, engineered autologous tumor cells,
targeting T cell-tumor interaction, stem cell transplantation
and treatment with cytokines [3].
B7 molecules are a growing protein family with diverse
functions on both immune and tumor cells. They play in
particular a key role in the crosstalk of the immune sys-
tem and cancer tissues in different tumor entities [4]. B7
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signal, the antigen recognition mediated by binding of the
T cell receptor (TCR) with the major histocompatibility
complex (MHC). These signals can be of co-inhibitory or
co-stimulatory nature. Interestingly, also a reverse signal-
ing in B7 family member expressing cells has been discov-
ered [5]. The B7 family comprises B7-1 (CD80), B7-2
(CD86), B7-H1 (PD-L1), B7-DC (PD-L2), B7-H2 (ICOS-L),
B7-H3, B7-H4 and B7-H6 [6,7]. Many tumors of distinct
origin express B7-H molecules, in particular B7-H1. There-
fore, monoclonal antibodies (mAb) targeting PDL1/B7-H1
on tumor cells or the PD1 receptor expressed by immune
cells have been developed for the treatment of tumors.
These antibodies are currently implemented in clinical tri-
als demonstrating promising objective response rates in
various tumors [8].
In the context of RCC B7-H1 expression of tumor le-
sions is associated with a worse prognosis of RCC pa-
tients [9]. The prognostic relevance of B7-H1 in RCC
was further strengthened by the fact that B7-H1 mRNA
is increased in early metastasis when compared to pri-
mary lesions suggesting that B7-H1 might serve as
marker of a metastatic signature in RCC [10].
Cytokines are a family of modulatory proteins or gly-
coproteins that bind to their respective receptors on a
variety of different immune and cancer cells thereby in-
ducing different downstream signaling processes. Studies
of cytokines are complicated due to their pleiotropy and
apparent redundancies of action [11].
Over two decades one conventional treatment regime for
patients with RCC included cytokines like IFN-α and IL-2.
Despite the results were promising in preclinical settings
[12-14], the clinical efficacy was rather poor with anti-
tumoral responses ranging between 10 – 20% [15-18]. This
might be due to the lack of knowledge of the tumor micro-
environment, the molecular alterations and heterogeneity
of tumors including those concerning the B7 family mem-
bers in tumor and immune cells upon cytokine treatment.
With the exception of interferon (IFN)-γ [19,20] the
effect of different cytokines on the regulation of B7-H
molecules on RCC cells is widely unknown. Therefore,
this study analyzed the regulation of B7-H molecules
upon cytokine treatment in RCC in detail. B7-H1 surface
expression was most dramatically altered upon IL-4 and
TNFα. This enhancement occurred at the transcriptional
level by direct upregulation of the B7-H1 promoter ac-
tivity, which was associated with an inhibition of T cell
proliferation.
Materials and methods
Cell lines and PBMC from healthy donors
The following RCC cell lines were used in the study and
originally established from RCC patients in Mainz (MZ)
or in Halle (Hal): MZ2514RC, MZ1257RC, MZ1790RC,MZ1774RC, MZ2733RC, MZ2877RC, Hal31RC, Hal162RC,
Hal87RC and Hal149RC. The two melanoma cell lines
BUF1088Mel and UKRV-Mel-14a have been recently
described [21] and were either a kind gift from S. Ferrone
(Pittsburgh, USA) or obtained from the European tumor
cell line data base (ESTAB project; see www.ebi.ac.uk/ipd/
estdab). Buffy coats were obtained from healthy donor
(HD) of the blood bank of the University Hospital Halle.
The Institutional Review Board (Ethics Committee) at the
University Hospital in Halle (Germany) approved this
study.
Reagents
Monoclonal antibodies (mAb) for flow cytometric analysis
were: αCD8, αHLA-I (clone B9.12.1), αCD40 and αICAM-
1 from Beckman Coulter (Krefeld, Germany); αPD1,
αCD80, αNF-κB (pS529), αIκB and αpSTAT6 from Becton
Dickinson (Heidelberg, Germany); αB7-H4 from AbD ser-
otec; αICOS, αB7-H4, αB7-H1, αB7-H2 and αCD107a
from ebioscience (Frankfurt, Germany); αB7-H3, αTNFRI
and fluorokine biotinylated human IL-4 staining kit
were used from R&D systems (Wiesbaden, Germany).
Respective isotypes were purchased from BD Bioscience
or Beckman Coulter, respectively. The antibodies were
used unconjugated and/or as direct conjugates with
FITC, Alexa-488, PE, APC or PE-Cy7. Recombinant
TNFα and IL-4 for the treatment of RCC cell lines were
purchased from ImmunoTools (Friesoythe, Germany).
IL-2 (Proleukine, Pharmacy, University of Halle, Germany),
phorbol myristate acetate (PMA), propidiumiodid and
ionomycin from Sigma-Aldrich (Steinheim, Germany)
were used. αCD8 microbeads were obtained from Miltenyi
Biotech (Gladbach, Germany). RPMI1640 and DMEM
were purchased from Invitrogen (Karlsruhe, Germany), X-
VIVO15 from Lonza (Basel, Switzerland). The fix and perm
kit for intracellular stainings was from BD Bioscience.
The following antibodies for cell culture were employed:
αCD3 (clone OKT3) and αB7-H1 (clone MIHI) from
ebioscience, purified mIgG1 and mIgG2a from Millipore
(Eschborn, Germany) and αHLA-I (clone w6/32) obtained
from culture supernatants of hybridomas.
Flow cytometry
Flow cytometric analyses were essentially performed as re-
cently described [21]. In brief, 1 × 105 cells were stained
with fluorescent-labeled antibodies, while dead cells were
excluded using PI staining. For determination of the IL-4
receptor expression an indirect staining method using
IL-4-biotin followed by Avidin-FITC according to man-
ufacturers’ protocols was employed. For intracellular
flow cytometric analyses of signal transduction compo-
nents paraformaldehyde-fixed tumor cells were used, sub-
sequently treated with permeabilizing buffer (methanol)
prior to antibody staining. Flow cytometry was performed
Quandt et al. Journal of Translational Medicine 2014, 12:151 Page 3 of 12
http://www.translational-medicine.com/content/12/1/151using either a FACSscan™, FACSCalibur™ or a FACSCanto™
(all Becton Dickinson) or FC500 (Beckman Coulter) flow
cytometer and CellQuest™ or CXP™ and FlowJo™ (Tree
Star) software, respectively.
Cytokine treatment of tumor cells
3×105 tumor cells/well were seeded into 6 well plates in
DMEM/10% FCS. Cytokines (IL-4 at 1000U/ml and TNFα
at 800 U/ml) were added the following day for 30 min or
4–72 hrs as indicated for the subsequent analysis.
PCR analysis
Total cellular RNA from frozen cell pellets was extracted
using RNAeasy MiniKit (Qiagen Hilden, Germany) and
reversely transcribed into cDNA (Fermentas, St. Leon-Rot
Germany) as recently described [22]. Semi-quantitative
RT-PCR from cellular RNA was performed using the
following oligonucleotide primers: For IL-4 fw: 3′ cagttc
tacagccaccatgaga 5′ rev: 3′ catgatcgtctttagcctttc 5′ for, IL-
4Rα fw: 3′ tctacttgcgagtggaagatga 5′ rev: 3′ ctccaaatgttgac
tgcatagg 5′, TNFα fw: 3′ gtgcttgttcctcagcctct 5′ rev: 3′ gctt
gtcactcggggttc 5′, TNFRI fw: 3′ gccaggagaaacagaacacc 5′
rev: 3′ gggataaaaggcaaagacca 5′ and for β-actin fw: 3′ tcct
gtggcatccacgaaact 5′ rev: 3′ gaagcatttgcggtggacgat 5′. Real-
time PCR (Cybr Green, Invitrogen) analysis for B7-H1
and B7-H4 from cellular RNA was performed using the
following oligonucleotide primers: H1: fw: 3′ gaactacctc
tggcacatcct 5′ rev: 3′ gcccattccttcctcttgtc 5′, H4: fw: 3′ agg
cttctctgtgtgtctcttc 5′ rev: 3′ cttgctcttgtttgctcactcc 5′.
Cloning of the reporter gene vector
Genomic DNA was isolated from the B7-H1 expressing
melanoma cell line UKRV-Mel-14a using the QIAamp
DNA Mini Kit (Qiagen) according the manufacturers’
protocol. The B7-H1 promoter was amplified by PCR
with Taq DNA polymerase Kit (Invitrogen) employing
the forward primer 5′-AAAGGTACCTAGAAGTTCAG
CGCGGGATA-3′ and the reverse primer 5′-AAAGGAT
CCCAGCGAGCTAGCCAGAGATA-3′. The specific PCR
product was purified and cloned into the pMiR REPORT
vector (Ambion, Austin, Texas, USA) using the restriction
enzymes KpnI and BamHI (Fermentas) replacing the CMV
promoter as recently described [23]. For replacing the
luciferase (luc) reporter gene by the red fluorescent m-
cherry protein, the m-cherry sequence was amplified
from the pmR-m-cherry vector (Clontech, Mountain View,
CA, USA) applying the forward primer 5′-AAAGGATC
CATGGTGAGCAAGGGCGAGGA-3′ and the reverse
primer 5′-AATGTGGTATGGCTGATTAT-3′. The PCR
product was digested with BamHI (Fermentas) and SpeI
(NEB, Ipswich, MA, USA) and cloned behind the B7-H1
promoter sequence in the pMiR REPORT backbone re-
placing the luciferase gene. The plasmid map is shown in
Additional file 1: Figure S1.Cell transfection
The reporter gene plasmid was stably transfected into the
melanoma cell line BUF1088Mel using the Effectene
Transfection Reagent (Qiagen, Hilden, Germany). Stable
transfectants were selected with puromycin (pur) and a
pur-resistant batch culture was generated. Transfected
cells were cytokine treated as described above and flow cy-
tometric analyses were performed 72 hrs post stimulation.
Tumor-T cell co-culture assays
Tumor cells were pretreated with cytokines as described
above, detached, washed with PBS (3 x times), counted
and seeded with 1 – 2 × 105 into 96 or 24 well plates.
Peripheral blood mononuclear cells (PBMC) were ob-
tained by Ficoll gradient from buffy coats of healthy vol-
unteers. T cells were sorted for CD8+ cells (purity > 98%)
and co-cultivated tumor cells as described [21]. For pro-
liferation assays, T cells were labeled with CDFA-SE
(Lifetechnologies, Darmstadt, Germany) according to
manufacturers’ instructions) and tumor cells were pre-
treated with αHLA-I or anti-B7-H1 for 30 min prior to
5 day co-culture assays. Proliferation data are presented
as division index (DI) that is the average number of cell
divisions that a cell in the original population has under-
gone. For the determination of IFNγ secretion tumor
cells were co-cultured with T cells for 4 hrs. Cell culture
medium for the coculture assays was X-VIVO15.
Detection of cytokine release
To determine IFN-γ secretion of T cells the IFN-γ secre-
tion assay (Miltenyi) was performed following the manu-
facturer’s instructions. T cells stimulated with PMA/
ionomycin (10 ng/ml and 1 μg/ml) served as a positive
control. TNFα production of tumor cells was analyzed
from culture supernatants using a TNFα-specific ELISA
according to manufacturer’s instructions (ebioscience).
Statistical analysis
Statistical analyses were performed using Prism 3.0 and
depending on controlled data normality distribution
Mann Whitney U Test or student’s t test was used.
Results
Cytokine receptor expression as a prerequisite for
cytokine activity in RCC cells
The constitutive expression of the IL-4 and TNFα recep-
tors and and their ligands were determined in RCC cell
lines. Using conventional qPCR TNFα, but not IL-4
mRNA expression levels were detected in the different
RCC cell lines (Figure 1A). Despite prominent TNFα
transcription rather low secretion levels of this cytokine
were detected in one/five RCC cell lines tested (Figure 1B).




























































Figure 1 Expression analysis of IL-4, TNFα and their receptors in RCC cell lines. A) Constitutive TNFα mRNA expression, but lack of IL-4
mRNA expression was determined by conventional qPCR in different RCC cell lines (Hal31RC, MZ1257RC, MZ2514RC, MZ1790RC, Hal161RC) and in
PBMC, which served as positive control. Representative data of at least 3 different experiments are shown. B) TNFα secretion of different RCC cell
lines TNFα secretion was determined in Hal31RC, MZ1257RC, MZ2514RC, MZ1790RC, Hal161RC using ELISA. Representative data out of at least 3
different experiments are shown. C) The IL-4Rα and TNFRI-α expression was determined by qPCR in the different RCC cell lines and in PBMC, which served
as positive control. Representative data of at least 3 different experiments are shown. D) Flow cytometric analyses of IL-4R and TNFαRI demonstrated
the constitutive expression of IL-4R and TNFRI on Hal31RC and Hal161RC. The results are expressed as histograms. Bold line: staining, thin line:
control. TNFRI is stained with an anti-TNFRI-PE labeled antibody, bold line: staining, thin line: isotype control. Representative data of at least 3
different experiments are shown.
Table 1 Constitutive B7-H1-B7-H4 expression in renal cell
carcinoma cell lines as determined by FACS, isotype control
stainings were implemented
cell lines B7-H1 B7-H2 B7-H3 B7-H4
Hal31RC + + ++ +/−
Hal78RC + + ++ +/−
Hal149RC + + ++ +/−
Hal162RC ++ ++ ++ +/−
MZ1774RC + + +++ +/−
MZ1790RC +/− ++ ++ +/−
MZ1257RC + + ++ +/−
MZ2514RC + + ++ +/−
MZ2733RC + + ++ +/−
MZ2877RC + + ++ +/−
+/− : 5-20% positive; +: 20-50% positive; ++ : > 50-100% positive; +++: 100%
positive, and staining intensity > 10 fold to isoytpe control.
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determined by qPCR and flow cytometry, respectively.
IL-4 and TNFα synergistically enhance B7-H1 expression
in RCC cells
A heterogeneous, but constitutive cell surface protein
expression of B7-H family members was detected in the
tested RCC cell lines (Table 1). While B7-H1 to B7-H4
were expressed on all RCC cell lines, the degree of ex-
pression was quite diverse with the highest levels for B7-
H3 followed by B7-H2 and B7-H1, whereas only weak,
but detectable B7-H4 expression levels were found
(Table 1). In addition, qPCR analysis revealed low B7-H4
mRNA levels (Additional file 2: Figure S2). 2/3 RCC lines
were also weakly positive for B7-DC (data not shown).
Upon treatment with either IL-4 and TNFα alone or in
combination, the B7-H molecule expression was differen-
tially affected: B7-H4 transcription (data not shown) and
protein expression (Figure 2) was unaltered by this cyto-
kine treatment. Despite high constitutive expression levels,
a slight cytokine-mediated induction of B7-H3 was shown,
which was most prominent in RCC31 upon IL-4 and
TNFα treatment. B7-H2 was induced by TNFα, but not byIL-4 in the RCC cell line analyses, while combined TNFα
with IL-4 treatment had no additional effects (Figure 2).
The most prominent induction was found for B7-H1 in
all RCC cell lines by treatment with either cytokine,
while combination treatment caused synergistic effects
Figure 2 Significant increase of B7-H1 surface expression by IL-4 and TNFα treatment of RCC cell lines. Different RCC cell lines (Hal31RC,
Hal161RC, MZ1790RC) were treated with either IL-4 or TNFα alone before B7-H expression was determined by flow cytometry as described in
Materials and Methods at 72 hrs. A) Shown are FACS histogram overlay plots for B7-H1, B7-H2, B7-H3 and B7-H4. Each plot shows overlay graphs,
depicting constitutive protein expression and expression upon single or combined cytokine treatment. Representative data of at least 3 different
experiments are shown. B) Cytokine-mediated induction of B7-H1 and B7-H2 in % using constitutive expression levels as reference value. Combined
data of 3 different experiments are given.
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with a < 6 fold increase in RCC31 cells (Figure 3A). Fur-
thermore, IFNγ treatment of RCC cells increased B7-
H1 mRNA and protein expression (data not shown)
confirming recent reports [19].
In addition, other cytokines like IFNα, IFNβ, TGFβ,
IL-6 and IL-10 were tested for their ability to modulate
B7-H expression on RCC cells, but none of them altered
the expression levels of these molecules. The lack of the
cytokine-mediated effects on B7-H family members was
specific, since these cytokines modulate e.g. HLA class I
molecule expression (data not shown).
Transcriptional control of cytokine-mediated induction of
B7-H1
To identify the kinetics of IL-4- and TNFα-mediated
regulation of B7-H1 expression RCC cells were treated
for different time points with IL-4 and TNFα alone or in
combination before qPCR and flow cytometry was per-
formed. Already 4 hrs post combined cytokine treatment
a significant induction of B7-H1 mRNA was detected(Figure 3B). Treatment with IL-4 alone only marginally
increased the B7-H1 transcript levels throughout the
time points tested, whereas TNFα alone induced a sig-
nificant increase in B7-H1 mRNA levels at 24 hrs post
treatment. Combined cytokine treatment had always the
strongest impact on B7-H1 mRNA (Figure 3B). An en-
hanced protein expression was only detected at later
time points, with a maximal induction at 72 hrs post cyto-
kine treatment. These results pointed towards a regulation
at the transcriptional rather than posttranscriptional level,
e.g., by protein stabilization.
In order to test B7-H1 regulation at the transcriptional
level in more detail, promoter binding prediction pro-
gram (TESS) was used to determine direct binding sites
for STAT6 (downstream of IL-4 signaling) and NFκB
(p65, downstream of TNFα) on the B7-H1 promoter
(−952 to −1 bp before transcript start). A weak binding
site for STAT6 (TTACAAGAA) and two overlapping
high affinity binding sites for NFκB (GGAAAGTCCA;
AGGAAAGTCCAAC) were found in the B7-H1 pro-
moter. One NFκB binding site in the B7-H1 promoter
A)
B7-H1


















































Figure 3 Time kinetic of B7-H1 expression and B7-H1 promoter targeting upon combined cytokine treatment with IL-4 and TNFα. A)
Hal31RC was treated with either IL-4 or TNFα alone and with the combination of the two cytokines. B7-H1 protein expression was analyzed at
the time points indicated by flow cytometry. Shown are fold increase in B7-H1 expression compared to untreated cells. Representative data of at
least 3 different experiments are shown. B) B7-H1 mRNA expression in Hal31RC upon treatment with either IL-4 or TNFα alone and with the
combination of the two cytokines for the time points indicated are shown. Using a B7-H1 plasmid as standard, B7-H1 transcript levels per 10.000
transcripts β-actin are shown. Data are obtained by real time PCR. Representative data of 3 different experiments are shown. C) BUF1088Mel was
transfected with the mCherry B7-H1 promoter construct and stimulated with IL-4 and TNFα. The mCherry fluorescence was measured after 72 hrs
by FACS and a representative histogram plot is depicted. The bar graph shows the combined result of a total of 3 independent assays.
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tubular cells [24].
Based on this finding B7-H1 promoter studies were per-
formed [25]. The wild type B7-H1 promoter construct
hooked to the mCherry fluorescent protein was stably trans-
fected into BUF088Mel cells (Additional file 1: Figure S1).
Transfectants were subsequently left untreated or treated
with either cytokine (IL-4 or TNFα) alone or in combination
before promoter activity was determined 72 hrs later. As
shown in Figure 3C, an enhanced B7-H1 promoter activity
as determined by flow cytometry of the mCherryfluorescence was found upon single and more pronounced
upon combined treatment with IL-4 and TNFα. This sug-
gests a transcriptional upregulation of B7-H1, which
might be mediated by activation of STAT6 and NFκB.
Alterations in pSTAT6, NFκB, LFA-1, CD40 and HLA class I
antigen expression levels upon treatment of RCC cells
with IL-4 and TNFα
In addition to the regulation of B7-H molecules by cyto-
kine treatment downstream signal cascade components
and other processes known to be of relevance for the T
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cells were investigated.
A growth inhibition of RCC cells was detected upon
IL-4 addition, which was not further pronounced in the
presence of TNFα (Additional file 3: Figure S3). In con-
trast, TNFα alone had no influence on the cell prolifera-
tion, which is in discrepancy to earlier published data
showing an increased proliferation upon TNFα treat-
ment, but a strong influence of the culture media condi-
tions were found [26].
Following IL-4 treatment alone or in combination with
TNFα phosphorylation of STAT6, a key signal molecule
downstream the IL-4 receptor, was detected by flow cy-
tometry (Figure 4A). A known key downstream effector
of TNFα signaling is represented by NFκB. An enhanced
expression and activation of NFκB was found in TNFα
as well as TNFα- and IL-4-treated RCC cells (Figure 4A).
Next to the upregulation of NFκB the inhibitory subunit
of NFκB, named IkB, was downregulated upon TNFα
treatment in RCC cells (data not shown). Downregula-
tion/degradation of IκB as a part of the classical NFκB






Figure 4 Involvement of signaling components and change of HLA-I,
with IL-4 and TNFα in RCC cell lines. Hal31RC was treated with either IL-
Intracellular pSTAT6 as well as NFκB (pS529) at 30 min post stimulation we
expression and black bold line represents cytokine-induced expression of eith
cells compared to medium control. Representative data of at least 5 diffe
72 hrs post cytokine treatment were analyzed by flow cytometry. Data are pre
these molecules on untreated Hal31RC. Data are mean ± SEM of 9 different eAdditional important molecules for T cell/tumor com-
munication are CD40, a costimulator of the TNF-R family,
the adhesion molecule CD54 (LFA-1) and HLA class I an-
tigens. As shown in Figure 4B all these surface molecules
were upregulated by the treatment of RCC cells with IL-4
and TNFα, either alone or in combination. The combined
treatment of IL-4 and TNFα had an additive (CD40, HLA
class I) or a synergistic effect (LFA-1) on the protein ex-
pression, respectively (Figure 4B).
B7-H1 blocks allospecific T cell proliferation
B7-H1 has been shown to modulate T cell responses.
[19,28] To test the functional consequences of increased
B7-H1 on RCC cells upon IL-4 and TNFα treatment co-
culture assays of tumor cells with allospecific T cells
were performed. A decreased CD8+ T cell proliferation
was detected upon co-cultivation of T cells with IL-4
pretreated as well as with IL-4 and TNFα pretreated
tumor cells (Figure 5A and B). The direct influence of
both cytokines on T cells was eliminated by 3 times
washing of cytokine-treated tumor cells, prior to co-
culture assays. The decreased proliferation of CD8+ TB)
CD40 and CD54 expression upon combined cytokine treatment
4 or TNFα alone and with the combination of the two cytokines. A)
re analyzed by flow cytometry. Gray filled graph represents constitutive
er signaling component. Numbers on gates are percentage of positive
rent experiments are shown. B) HLA class I, CD40, CD54 expression
sented as fold increase when compared to constitutive expression of
xperiments.
Figure 5 Block of allogeneic CD8+ T cell proliferation upon coculture with RCC cells pretreated with IL-4 and TNFα. A-C) Hal31RC cells
were treated with either IL-4 or TNFα alone and with the combination of both cytokines. CD8+ T cells from allogeneic PBMCs were sorted, CFDA-SE
labeled and cocultured with cytokine pretreated RCC31Hal. A) Representative FACS histogramm plots of proliferated CD8+ Tcells cocultured with
untreated (u RCC) as compared to IL-4 or TNFα pretreated Hal31RC (4 + T RCC) are shown. The division index (DI) is given. B) Summary of CD8+ T
cell proliferation on cytokine pretreated Hal31RC. The division index (DI) is given. Pan anti-HLA class I antibody (w6/32) served as specificity control.
Data are means of 4 different donors ± SEM. C) Partial reversal of T cell proliferation inhibition upon coculture of CD8+ T cells with anti-B7-H1 antibody
or respective isotype control preincubated Hal31RC. Hal31RC were pretreated with IL-4 and TNFα for 3 days. Data represent the mean of 3 different
donors ± SEM. D) Analyses of constitutive B7H ligand expression, ICOS, CD80 and PD-1 on allogeneic CD8+ T cells prior to coculture with RCC31. Data
represent means of 7 different donors ± SEM. E) IFNγ production of isolated CD8+ T cells upon coculture of cytokine pretreated Hal31RC cells. Data are
means of 3 different donors ± SEM.
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tumor cells could be partially converted by the use of an
anti-B7-H1 blocking antibody as proof for the inhibitory
role of B7-H1 on tumor cells (Figure 5C).
To identify the possible binding partner of B7-H1 on
T cells, an anti-PD1 antibody was used for staining to
detect the most likely candidate PD1. Indeed, PD1 was
expressed in 10.05 ± 1.17% of CD8+ T cells analyzed
(Figure 5D). Since CD80 expression on T cells has been
postulated [29] and CD80 can additionally bind B7-H1
[30] its CD80 expression was determined on T cells. In
addition, since B7-H2 expression is known to be in-
creased upon treatment with TNFα, ICOS, the ligand of
B7-H2 was analyzed on CD8+ T cells prior to co-culture
assays. As shown in Figure 5D, CD80 and ICOS were
only very weakly expressed on CD8+ T cells.Important CD8+ T cell effector functions are cytokine
production and the ability to kill target cells. As determined
flow cytometry IFNγ secretion by CD8+ T cells was un-
altered upon co-culture with cytokine-treated RCC cells
(Figure 5E). Furthermore, the killing ability of CD8+ T cells
was determined by measurement of CD107a degranula-
tion, CD8+ T cells upregulated CD107a expression upon
co-culture with RCC cells, but no specific changes with re-
spect to co-culture with cytokine pretreated tumor cells
were found (data not shown).
Discussion
The present study was undertaken to discover the distri-
bution and regulation of B7-H family members in RCC
by cytokines released from immune cells of the tumor
microenvironment. Interesting, a synergistic increase of
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with IL-4 and TNFα was found. As early as 4 hrs after
treatment, B7-H1 mRNA was significantly enhanced
resulting in 6- fold increase in protein surface expression
by 72 hrs and was mediated by an upregulation of the
B7-H1 promoter activity by combined IL-4 and TNFα
treatment. In addition, the increase in B7-H1 protein
surface expression on RCC cells was associated with a
decreased allospecific T cell proliferation upon co-
culture experiments.
Detailed analysis showed a constitutive, but variable
surface expression of B7-H1 to B7-H4 molecules on
RCC cells. Expression of B7-H1, B7-H3 and B7-H4 in
situ has been correlated with a worse clinical outcome
of RCC patients [9,31,32]. In all tested RCC cell lines,
B7-H4 was rather weakly expressed. In contrast B7-H3
was strongly expressed on RCC cell lines. To the best of
our knowledge, we are the first to show B7-H2 expression
on RCC cells. There exist random reports showing expres-
sion of this molecule in human tumors such as glioblast-
oma [33] and melanoma [34]. B7-H2 on glioma cells leads
to an increase in T cell-mediated anti-tumor immunity [35].
In addition, B7-H1 expression on RCC cells was con-
firmed with a weak or intermediate expression level by
all RCC cell lines tested. Testing of the constitutive cyto-
kine expression revealed a weak TNFα production by
one RCC cell line, while all others were negative. These
data are in line with earlier reports describing that some
RCC cells are able to produce TNFα [36]. Furthermore,
RCC cells in our study lack IL-4 expression thereby con-
firming previous published data [37]. A prerequisite to
respond to a particular cytokines is the expression of the
respective cytokine receptors. Both the IL-4R as well as
TNFRI expression was found on all RCC cells tested.
TNFα acts via TNFRI and II both expressed on RCC
cells [38]. IL-4R expression on RCC cells in vitro and in
situ has been demonstrated before [39]. Interestingly,
structural differences for IL-4R on RCC cells when com-
pared to immune cells exist, which might partially ex-
plain the differential outcome of IL-4 action in these
cells [37]. Most of the RCC cell lines tested in the
present study showed a very good and reliable response
to IL-4 and TNFα treatment as demonstrated by phos-
phorylation of STAT6, enhancement of pNFκB and
downregulation of IkB.
Given the importance of B7-H molecules for the out-
come of RCC patients and the presence of cytokines in
the tumor microenvironment, the regulation of these
family members upon treatment with various cytokines
was determined. As already described, upregulation of
B7-H1 expression by IFNγ was confirmed [19]. In
addition the most prominent effect on the regulation of
B7-H1 was found using combined IL-4 and TNFα treat-
ment. B7-H1 was transcriptionally controlled by thesecytokines. B7-H2 was only upregulated by TNFα treat-
ment, but not by IL-4.
IL-4 and TNFα can both be produced by different im-
mune cells and thus represent components of the tumor
microenvironment. In RCC TNFα is produced by tumor-
associated macrophages (TAM) [40]. TAMs can be subdi-
vided into classical M1 phenotype macrophages that pro-
duce and dependent on proinflammatory cytokines, such
as TNFα and into alternative M2 phenotype macrophages
[41]. M2 macrophages are characterized by the production
of IL-10, TGF-β and are induced by IL-4. The ratio of M1/
M2 TAMs together with the number and phenotype of
dendritic cells, myeloid derived suppressor cells (MDSC)
and the Th1/Th2 balance determine the cytokine milieu
and thereby the anti-tumor response in the tumor micro-
environment. Already 15 years ago CD4+ Th cells of the
Th1 (predominantly IFNγ) and Th2 (predominantly IL-4)
cells as well as CD8+ T cells have been shown to play a
key role for an effective anti-tumor response. Further-
more, IL-4 has a tremendous impact on the anti-tumor
immunity by shifting the Th1/Th2 balance [42]. The im-
portance for IL-4 in RCC is demonstrated by the existence
of a functional polymorphism in the IL-4 gene (−590 T)
leading to an enhanced expression of this cytokine, which
is correlated with an increased risk of developing RCC
[43] and a decreased survival [44] when compared to RCC
patients carrying the other haplotype (−590C). In contrast
to earlier reports, IL-4 can reduce tumor growth suggest-
ing that the time point and local distribution of high IL-4
levels have an impact on RCC progression. Of importance,
microarray data reveal a positive correlation of B7-H1
with TNFα, NFkB and STAT6 (http://r2.amc.nl) in kidney
tumor tissue in vivo, nicely supporting our data of a linked
B7-H1 expression with these cytokines.
In addition to IFN-γ, the regulation of B7-H expres-
sion by cytokines has been studied earlier, but mostly on
immune cells and not on RCC cells. Kryzek and co-
authors showed an increase of B7-H4 in TAMs upon
treatment with IL-6 or IL-10 [45]. Similar to our find-
ings TNFα upregulates B7-H2 on embryonic fibroblasts
[46] and endothelial cells [47], while IL-4 did not modu-
late B7-H2 and the combined treatment had no add-
itional effect [47]. Interestingly, on human endothelial
cells TNFα together with IFNγ synergistically affect in-
duction, whereas TNFα alone did not induce any B7-H1
expression [48].
As already proposed by and confirmed in this study
combined IL-4 and TNFα treatment exerts a synergistic
effect on the increase of HLA class I antigen expression
in RCC cells, which might enhance T cell-based anti-
tumor responses [13]. This was further supported by an
increased expression of components of the APM leading
to increased HLA class I surface antigen expression in
RCC cells upon IFN-γ treatment [30]. Since another
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ICAM1 expression was analyzed. ICAM1 expression was
highly upregulated upon combined IL-4 and TNFα treat-
ment, which can support T cell/tumor interaction. This is
in line with published data demonstrating that TNFα in-
duces ICAM1 expression [49].
As functional consequences of cytokine-mediated en-
hanced B7-H1 on RCC tumor cells, a decreased allospe-
cific CD8+ T cell proliferation was found, which could
be partially converted by addition of an anti-B7-H1 anti-
body. Since PD1 was the only substantially expressed re-
ceptor on the CD8+ T cells used in the co-culture assays,
it is therefore most likely responsible for this effect. This
assay nicely resembles the in vivo situation, since en-
hanced PD1 expression on tumor-infiltrating immune
cells has been found in RCC and could be associated
with poor patients’ prognosis [50]. However, IFN-γ and
CD107a mobilization was not altered in CD8+ T cells
upon co-culture with cytokine pre-treated tumor cells.
An inhibitory effect of B7-H1 on CD8+ T cells has already
been described in different studies. A block in T cell pro-
liferation owing to B7-H1 has been shown before with
overexpression or blocking of B7-H1, but not with
cytokine-pretreated cells [51,52,20]. Additionally, a dir-
ect decrease of CD8+ T cell killing and cytokine pro-
duction upon co-culture assays with anti-B7-H1
blocking antibody for human TCR tg CD8+ T cells in
RCC has been found [19]. On the other hand, Dong
and coworkers (2002) showed that TCR tg human CTL
are equally able to kill B7-H1 over-expressing melan-
oma cells, but a B7-H1 dependent induction of T cell
apoptosis was detected [28]. Together with the findings
of this study the data demonstrate the powerful influ-
ence of B7-H1 on the modulation of different T cell ef-
fector responses, which highly appear to depend on the
co-culture systems chosen.
The observed block of T cell proliferation on CD8+ Tcells
co-cultured with single IL-4-treated RCC cells could be
due to an additionally interaction of PD1 on T cells
with its second ligand B7-DC. A weak constitutive ex-
pression of B7-DC was found that could be also a subject
to regulation by IL-4 similar as shown for macrophages
[53] possibly not to TNFα as analyzed for monocytes [52].
B7-DC has been shown to inhibit human T cell prolifera-
tion by PD1 binding [51].
High dose TNFα has been used to treat solid tumors,
but due to many side effects upon systemic administra-
tion the success rate has been rather low, and strategies
to administer this cytokine more locally had been devel-
oped for e.g. melanoma patients [54], but have not been
used to treat RCC.
Phase II clinical trials using IL-4 for the treatment of
RCC were not beneficial for these patients [16,18].
This might be at least partially explained by thedecreased T cell proliferation capacity upon co-culture
assays with IL-4-treated RCC cells. TNFα alone had no
effect on T cell effector responses in the setting used
in our study, although TNFα treatment exerted benefi-
cial anti-tumor effects in a xenograft mouse model
with RCC tumors [12].
Conclusion
Concluding the data, this study showed for the first time a
detailed analysis of B7-H molecule regulation upon cyto-
kine treatment in RCC. B7-H1 exhibited the strongest sen-
sitivity to IL-4 and TNFα by a synergistic upregulation in
RCC cells and is controlled at the transcriptional level by
direct promoter targeting. The importance of this B7-H1
induction is demonstrated by an inhibition of T cell prolif-
eration thereby contributing to the proposed significance
of B7-H1 in cancer immunity. The study furthermore sup-
ports the rational of using B7-H1/PD1 checkpoint anti-
bodies for the treatment of tumor patients.
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